Ultrasound-Guided Serratus Plane Block Vs Paravertebral Block For Chronic Post-mastectomy Pain.

Sponsor
Assiut University (Other)
Overall Status
Unknown status
CT.gov ID
NCT04317898
Collaborator
(none)
50
2
11

Study Details

Study Description

Brief Summary

compare the analgesic efficacy between ultrasound paraverbral block and serratus block in post mastectomy pain.

Condition or Disease Intervention/Treatment Phase
  • Procedure: serratus plane block by ultra-sound
  • Procedure: paravertebral block by ultra-sound
N/A

Detailed Description

It is reported that postmastectomy pain syndrome (PMPS) is a common problem, ranging from 25% to 60%.

The pain is localized in the axilla, medial upper arm, breast, and/or chest wall and lasting beyond three months after surgery when all other causes of pain such as infection have been eliminated.

The pain seriously affects the patient's mood, everyday activities, and social function and causes heavy economic burden for the healthcare system.

Postmastectomy pain syndrome (PMPS) itself is not a specific diagnosis but rather describes a cluster of symptoms frequently observed in breast cancer survivors following treatment.

Many patients will experience short-term nociceptive pain after breast cancer treatment. However, with PMPS, patients frequently experience persistent neuropathic-type pain: burning, tingling, aching, a subjective sense of "tightness" around the chest wall, or even phantom breast or nipple pain. Neuropathic pain results from dysfunction of the peripheral nerves caused by surgery, radiation, or neurotoxic chemotherapies.

Currently, there are a wide variety of approaches to treat this type of pain. physical therapy has been employed as a modality to improve physical function.

As far as interventional procedures, intercostal nerve blockade, stellate ganglion blockade, and paravertebral blockade have all been utilized with varying degrees of success.

Paraverberal blocks have superseded thoracic epidurals when it comes to choice of a regional anaesthesia technique to provide analgesia for breast surgery.

The injection of local anaesthetic solution in the paravertebral space results in a unilateral block, which is sensory, motor, and sympathetic. The uptake of the local anaesthetic solution is enhanced due to the absence of fascial sheaths binding the spinal nerves.

Another potential target for an interventional procedure for chronic pain after treatment for breast cancer is the serratus plane. The serratus plane block is a novel ultrasound-guided nerve block, which is able to anesthetize the hemithorax.

The serratus plane block relies on the fact that there are branches of the intercostal nerves following within 2 potential spaces, one superficial and one deep, surrounding the serratus anterior muscle. The serratus anterior muscle arises as strips from the first 9 ribs and converges posteriorly on the scapula to form the medial wall of the axilla.

The innervation of the serratus anterior muscle is via the long thoracic nerve (Bell's nerve), and the nerve itself is covered by the fascia of the serratus anterior muscle and lies anterior to the muscle.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Treatment
Official Title:
Ultrasound-Guided Serratus Plane Block Vs Paravertebral Block For Chronic Post-mastectomy Pain.
Anticipated Study Start Date :
Jul 1, 2020
Anticipated Primary Completion Date :
Apr 1, 2021
Anticipated Study Completion Date :
Jun 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: serratus plane block

20 ml of Bupivacine 0.25% +80mg triamcinlone will be injected in serratus plane under ultrasound.

Procedure: serratus plane block by ultra-sound
To perform Serratus block, patients will be placed in the lateral decubitus position with the affected side facing up, or in the prone position with the affected side facing the operator . After sterile preparation, a linear ultrasound probe will be utilized to identify the latissimusdorsi and serratus anterior muscles in a sagittal plane. The plane superficial to the serratus anterior muscle and below the latissimusdorsi muscle will be identified. The skin will be topicalized with 1 mL of 1% lidocaine using a 30-gauge needle. Using an in-plane approach, a 25-gauge 1.5-cm needle will be used to inject a total of 20-mL of 0.25% bupivacaine with 80 mg of triamcinlone under direct ultrasound visualization.

Active Comparator: paravertebral block

10 ml of bubivacine 0.25% +80 mg triamcinlone will be injected at T2 level (paravertebral) under ultrasound.

Procedure: paravertebral block by ultra-sound
TPVB will be given using high frequency linear US transducer, place the probe parallel to the vertebral spine at T2 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of plura, transverse process and paravertebral space, the needle will be inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 10ml of 0.25% bubivacine and 80mg triamcinlone slowly; the pleura will be seen to be pushed downward.

Outcome Measures

Primary Outcome Measures

  1. Percentage of patients gaining ≥ 50% pain reduction at VAS Score from baseline value. [baseline]

    Compare the analgesic efficacy between ultrasound paraverbral block and serratus block in chronic postmastectomy pain.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients have postmastectomy pain of neuropathic nature, DN4

  • 4 for at least 3ms duration.

  • The intensity of postmastectomy pain on VAS score ≥ 5.

  • Unsatisfactory treatment with 1st line antineuropathic drugs, Pregabalin(150 mg daily) or Deloxetine(60mg daily).

Exclusion Criteria:
  • Infection of the skin at or near site of needle puncture.

  • Coagulopathy .

  • Drug hypersensitivity or allergy to the studied drugs.

  • Central or peripheral neuropthy .

  • Significant organ dysfunction .

  • Morbid obesity (BMI>35kg/m2) .

  • Vertebral anomalies.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Assiut University

Investigators

  • Study Director: Mohammed Mohammed Abd El-Latif, Prof of Anesthesia, Mohammed MohammedAbd El-Latif
  • Study Director: Ashraf Amin Mohammed, Prof of Anesthesia, Ashraf Amin Mohammed
  • Study Director: Rania Mohammed Abd El-Emam, Lecturer of Anesthesia, Rania Mohammed Abd El-Emam

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Aya Abo eldahab Ali elden, principal investigator, Assiut University
ClinicalTrials.gov Identifier:
NCT04317898
Other Study ID Numbers:
  • analgesia in chronic PMPs
First Posted:
Mar 23, 2020
Last Update Posted:
Jul 15, 2020
Last Verified:
Jul 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Jul 15, 2020